First Phase III for Resected CRC ctDNA-Guided Therapy Shows Mixed Results
The ALTAIR trial found that FTD/TPI did not improve disease-free survival in resected stage I–IV colorectal cancer patients who were ctDNA-positive by Natera's...
The ALTAIR trial found that FTD/TPI did not improve disease-free survival in resected stage I–IV colorectal cancer patients who were ctDNA-positive by Natera's Signatera test. The post First Phase III for Resected CRC ctDNA-Guided Therapy Shows Mixed Results appeared first on Inside Precision Medicine .